---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-087118"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2024-07-29T23:59:59+00:00"
generated_at: "2026-05-31T15:53:58.038540+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Achieve Life Sciences enters $10M convertible debt agreement with Silicon Valley Bank, up to $20M total

## Summary
- Initial $10M term loan funded July 25, 2024; up to $10M additional subject to FDA NDA acceptance and lender approval.
- Interest at greater of 7.0% or prime minus 1.0%; interest-only until Dec 31, 2025; maturity Dec 1, 2027 (extendable to Jun 1, 2028).
- Conversion rights: initial conversion price $7.00/share, up to 1.43M shares; subsequent tranches at higher of $4.854 or 150% of trailing 10-day VWAP.
- Refinanced prior 2023 convertible debt of $16.6M; obligations satisfied and terminated.
- Registration rights granted to lender for resale of conversion shares.

## SEC filing metadata
- accession: 0000950170-24-087118
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2024-07-29T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.03, 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000095017024087118/0000950170-24-087118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000095017024087118/achv-20240725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-087118
- JSON: https://secwatch.observer/filing/0000950170-24-087118.json
- Plain text: https://secwatch.observer/filing/0000950170-24-087118.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.